<PAGE>
                                                                   EXHIBIT 10.10


                                  FORM OF NOTE

THE SECURITIES, IN THE FORM OF THE PROMISSORY NOTE OF MOLECULAR DIAGNOSTICS,
INC., HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES CANNOT BE SOLD, TRANSFERRED,
ASSIGNED OR OTHERWISE DISPOSED, EXCEPT IN ACCORDANCE WITH THE SECURITIES ACT OF
1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS.

                                 PROMISSORY NOTE

                                                               Chicago, Illinois
                                                              (DateofNote), 2002

         FOR VALUE RECEIVED, MOLECULAR DIAGNOSTICS, INC, a Delaware corporation,
414 North Orleans Street, Suite 510, Chicago, Illinois 60610, and its successors
and assigns, (the "Company") promises to pay to the order of (Name)
("Holder"), at (Address1), or at such other place as Holder may from time to
time designate in writing, the principal sum of (Amtfull) Dollars ($(Amt))
in lawful money of the United States of America, together with interest on so
much thereof as is from time to time outstanding at the rate hereinafter
provided, and payable as hereinafter provided. This Note is one of a series of
Notes containing the same terms as this Note.

1.   Interest Rate. The unpaid principal balance of this Note shall bear
     interest at the rate of seven percent (7%) per annum, simple interest.
     Interest shall be paid in cash or stock at the option of the holder at the
     Maturity of the Note.

2.   Payment/Maturity Date. The total outstanding principal balance hereof,
     together with accrued and unpaid interest, shall be due and payable on July
     30, 2002.

3.   Conversion. The Notes will automatically convert as described in the Term
     Sheet attached to the Subscription Agreement.

4.   Default Interest and Attorney Fees. Upon declaration of a default
     hereunder, the balance of the principal remaining unpaid, interest accrued
     thereon, and all other costs, and fees shall bear interest at the rate of
     eighteen percent (18%) per annum from the date of default, or the date of
     advance, as applicable. In the event of default, the Company and all other
     parties liable hereon agree to pay all costs of collection, including
     reasonable attorneys' fees.

5.   Interest Calculation. Daily interest shall be calculated on a 365-day year
     and the actual number of days in each month.

6.   Prepayment. This Note may be prepaid in whole or in part.

7.   Costs of Collection. Company agrees that if, and as often as, this Note is
     placed in the hands of an attorney for collection or to defend or enforce
     any of Holder's rights hereunder or under any instrument securing payment
     of this Note, Company shall pay to Holder its reasonable attorneys' fees
     and all court costs and other expenses incurred in connection therewith,
     regardless of whether a lawsuit is ever commenced or whether, if commenced,
     the same proceeds to judgment or not. Such costs and expenses shall
     include, without limitation, all costs, reasonable attorneys' fees, and
     expenses incurred by Holder in connection with any insolvency, bankruptcy,
     reorganization, foreclosure, deed in lieu of foreclosure or similar
     proceedings involving Company or any endorser, surety, guarantor, or other
     person liable for this Note which in any way affect the exercise by Holder
     of its rights and remedies under this Note, or any other document or
     instrument securing, evidencing, or relating to the indebtedness evidenced
     by this Note.

8.   Default. At the option of Holder, the unpaid principal balance of this Note
     and all accrued interest thereon shall become immediately due, payable, and
     collectible, with written notice of default and demand, and with five days




<PAGE>

     notice to cure any default, upon the occurrence at any time of any of the
     following events, each of which shall be deemed to be an event of default
     hereunder:

     a.  Company's failure to make any payment of principal, interest, or other
         charges on or before the date on which such payment becomes due and
         payable under this Note.

     b.  Company's breach or violation of any agreement or covenant contained in
         this Note, or in any other document or instrument securing, evidencing,
         or relating to the indebtedness evidenced by this Note.

     c.  Dissolution, liquidation or termination of Company.

9.   Application of Payments. Any payment made against the indebtedness
     evidenced by this Note shall be applied against the following items in the
     following order: (1) costs of collection, including reasonable attorney's
     fees incurred or paid and all costs, expenses, default interest, late
     charges and other expenses incurred by Holder and reimbursable to Holder
     pursuant to this Note (as described herein); (2) default interest accrued
     to the date of said payment; (3) ordinary interest accrued to the date of
     said payment; and (4) finally, outstanding principal.

10.  Assignment and Transferability of Note. Company may assign this Note to any
     entity that acquires Company or substantially all of Company's assets.
     Holder may not transfer the Note in any manner without the written
     agreement of the Company.

11.  Non-Waiver. No delay or omission on the part of Holder in exercising any
     rights or remedy hereunder shall operate as a waiver of such right or
     remedy or of any other right or remedy under this Note. A waiver on any one
     or more occasion shall not be construed as a bar to or waiver of any such
     right and/or remedy on any future occasion.

12.  Maximum Interest. In no event whatsoever shall the amount paid, or agreed
     to be paid, to Holder for the use, forbearance, or retention of the money
     to be loaned hereunder ("Interest") exceed the maximum amount permissible
     under applicable law. If the performance or fulfillment of any provision
     hereof, or any agreement between Company and Holder shall result in
     Interest exceeding the limit for Interest prescribed by law, then the
     amount of such Interest shall be reduced to such limit. If, from any
     circumstance whatsoever, Holder should receive as Interest an amount that
     would exceed the highest lawful rate, the amount that would be excessive
     Interest shall be applied to the reduction of the principal balance owing
     hereunder (or, at the option of Holder, be paid over to Company) and not to
     the payment of Interest.

13.  Purpose of Loan. Company certifies that the loan evidenced by this Note is
     obtained for business or commercial purposes and that the proceeds thereof
     will not be used primarily for personal, family, household, or agricultural
     purposes.

14.  Governing Law. As an additional consideration for the extension of credit,
     Company and each endorser, surety, guarantor, and any other person who may
     become liable for all or any part of this obligation understand and agree
     that the loan evidenced by this Note is made in the State of Illinois and
     the provisions hereof will be construed in accordance with the laws of the
     State of Illinois, and such parties further agree that in the event of
     default this Note may be enforced in any court of competent jurisdiction in
     the State of Illinois, and they do hereby submit to the jurisdiction of
     such court regardless of their residence or where this Note was executed or
     any endorsement hereof may be executed.

15.  Arbitration. If at any time during the term of this Note any dispute,
     difference, or disagreement shall arise upon or in respect of the Note, and
     the meaning and construction hereof, every such dispute, difference, and
     disagreement shall be referred to a single arbiter agreed upon by the
     parties, or if no single arbiter can be agreed upon, an arbiter or arbiters
     shall be selected in accordance with the rules of the American Arbitration
     Association and such dispute, difference, or disagreement shall be settled
     by arbitration in accordance with the


                                       2
<PAGE>
     then prevailing commercial rules of the American Arbitration Association,
     and judgment upon the award rendered by the arbiter may be entered in any
     court having jurisdiction thereof.

16.  Binding Effect. The term "Company" as used herein shall include the
     original Company of this Note and any party who may subsequently become
     liable for the payment hereof as an assumer with the consent of the Holder,
     provided that Holder may, at its option, consider the original Company of
     this Note alone as Company unless Holder has consented in writing to the
     substitution of another party as Company. The term "Holder" as used herein
     shall mean Holder or, if this Note is transferred, the then Holder of this
     Note.

17.  Relationship of Parties. Nothing herein contained shall create or be deemed
     or construed to create a joint venture or partnership between Company and
     Holder. Holder is acting hereunder as a lender only.

18.  Severability. Invalidation of any of the provisions of this Note or of any
     paragraph, sentence, clause, phrase, or word herein, or the application
     thereof in any given circumstance, shall not affect the validity of the
     remainder of this Note.

19.  Amendment. This Note may not be amended, modified, or changed, except only
     by an instrument in writing signed by both of the parties.

20.  Time of the Essence. Time is of the essence for the performance of each and
     every obligation of Company hereunder.

     IN WITNESS WHEREOF, the undersigned has executed this Note as of
(DateofNote), 2002.

                                                    MOLECULAR DIAGNOSTICS, INC.
                                                    A Delaware corporation



                                                    By:
                                                       -------------------------
                                                          Peter Gombrich, CEO




                                       3